Bausch + Lomb Refinances $2.8B Term Loans, Securing Lower Interest Rates and Extended Maturity

summarizeSummary

Bausch + Lomb, a subsidiary of Bausch Health Companies Inc., successfully refinanced $2.8 billion in term loans, achieving reduced interest margins and extending the maturity date for a portion of the debt.

check_boxKey Events

• Debt Refinancing Completed

  Bausch + Lomb Corporation, a subsidiary, entered into a Fourth Amendment to its Credit and Guaranty Agreement, refinancing $2,802,125,000 in term loans.

• Reduced Interest Margins

  The refinancing includes a 0.50% per annum reduction from the applicable margin on Third Amendment Term Loans and a 0.25% reduction from First Incremental Term Loans.

• Maturity Extended for Some Debt

  The maturity date for the First Incremental Term Loans was effectively extended from September 29, 2028, to January 15, 2031, aligning with the Third Amendment Term Loans' maturity.

auto_awesomeAnalysis

This refinancing is a significant positive development for Bausch Health Companies Inc. and its subsidiary, Bausch + Lomb. By securing a new $2.8 billion tranche of term loans, the company has successfully addressed a substantial portion of its existing debt, which is comparable to its current market capitalization. The reduction in interest margins will lead to lower interest expenses, improving profitability and cash flow. Furthermore, extending the maturity of the First Incremental Term Loans from 2028 to 2031 enhances the company's financial flexibility and reduces near-term refinancing risk. This transaction demonstrates the company's ability to access capital markets on favorable terms, which is crucial for its long-term financial stability.